Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Rosa, Roberta, Damiano, Vincenzo, Formisano, Luigi, Nappi, Lucia, Marciano, Roberta, Veneziani, Bianca Maria, De Placido, Sabino, Bianco, Roberto
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Landes Bioscience 2013
Konular:
Author's View
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782521/
https://ncbi.nlm.nih.gov/pubmed/24083076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.25123
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller